Type 2 Diabetes

Hypercortisolism is prevalent among nearly one-quarter of people with difficult-to-control type 2 diabetes enrolled in a prospective phase 4 study, according to an industry press release.

Adherence to treatment with glucagon-like peptide-1 receptor agonists may lower the long-term risk for major adverse liver outcomes among patients with chronic liver disease and type 2 diabetes, according to data in Gut.

Most adults with type 2 diabetes and obesity who undergo gastric bypass achieve continued diabetes remission, even after weight regain, according to study findings published in the Journal of the American College of Surgeons.

Adults with type 2 diabetes and chronic kidney disease derive similar cardiovascular and kidney benefits from finerenone, regardless of their level of insulin resistance, according to findings published in Diabetes Care.

The risk for developing chronic kidney disease or cardiovascular disease is much lower among adults who achieve type 2 diabetes remission compared with those who do not, according to a post hoc analysis of the Look AHEAD trial.

Adults who achieve type 2 diabetes remission are less likely to develop chronic kidney disease and cardiovascular disease, according to study findings published in Diabetologia.

Adults who lose any amount of weight 1 year after being diagnosed with type 2 diabetes are more likely to achieve diabetes remission than those who gain weight, according to study data published in PLOS Medicine.

The risk for developing type 2 diabetes is substantially higher for adolescents with overweight or obesity and an HbA1c of at least 6.1% compared with those with an HbA1c of 5.5% or less, according to study data.

Sodium-glucose cotransporter-2 inhibitors and glucagon-like peptide-1 receptor agonists were associated with lower risk for cardiovascular events in type 2 diabetes, with or without metabolic dysfunction-associated steatotic liver disease.